

Jonathan Barratt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6732681/publications.pdf>

Version: 2024-02-01

195
papers

11,034
citations

46984

47
h-index

33869

99
g-index

202
all docs

202
docs citations

202
times ranked

6980
citing authors

#	ARTICLE	IF	CITATIONS
1	Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. American Journal of Kidney Diseases, 2022, 79, 570-581.	2.1	15
2	New Insights into the Pathogenesis and Treatment Strategies in IgA Nephropathy. Glomerular Diseases, 2022, 2, 15-29.	0.2	3
3	Relationship between immunoglobulin A1 lectin-binding specificities, mesangial C4d deposits and clinical phenotypes in immunoglobulin A nephropathy. Nephrology Dialysis Transplantation, 2022, 37, 318-325.	0.4	5
4	Immunological drivers of IgA nephropathy: Exploring the mucosa-kidney link. International Journal of Immunogenetics, 2022, 49, 8-21.	0.8	21
5	Three-Year Clinical Outcomes of the First South Asian Prospective Longitudinal Observational IgA Nephropathy Cohort. Kidney International Reports, 2022, 7, 305-318.	0.4	5
6	Rapidly progressive IgA nephropathy: clinicopathological characteristics and outcomes assessed according to the revised definition of the KDIGO 2021 Guideline. Nephrology Dialysis Transplantation, 2022, 37, 2429-2437.	0.4	2
7	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers. Kidney International Reports, 2022, 7, 993-1003.	0.4	18
8	Further Evidence for the Mucosal Origin of Pathogenic IgA in IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2022, 33, 873-875.	3.0	6
9	A Core Outcome Set for Trials in Glomerular Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 53-64.	2.2	4
10	Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy. Kidney International, 2022, 102, 160-172.	2.6	25
11	Recurrence of IgA nephropathy after kidney transplantation: experience from the Swiss transplant cohort study. BMC Nephrology, 2022, 23, 178.	0.8	7
12	MO209: Baseline Characteristics of Adults Enrolled in the Ongoing Phase 3 Randomized, Double-Blind, Active-Control Trial of Sparsentan For the Treatment of Immunoglobulin A Nephropathy (PROTECT). Nephrology Dialysis Transplantation, 2022, 37, .	0.4	1
13	Randomized Phase II JANUS Study of Atacicept in Patients With IgA Nephropathy and Persistent Proteinuria. Kidney International Reports, 2022, 7, 1831-1841.	0.4	32
14	International Physicians Delphi Survey: Managing Patients With IgA Nephropathy. Kidney International Reports, 2022, 7, 2076-2080.	0.4	1
15	Innovating and invigorating the clinical trial infrastructure for glomerular diseases. Kidney International, 2021, 99, 519-523.	2.6	4
16	Corticosteroids Should Be Used to Treat Slowly Progressive IgA Nephropathy: CON. Kidney360, 2021, 2, 1081-1083.	0.9	3
17	Epidemiology, baseline characteristics and risk of progression in the first South-Asian prospective longitudinal observational IgA nephropathy cohort. Kidney International Reports, 2021, 6, 414-428.	0.4	11
18	Multimethods study comparing the experiences of medical clinical academics with nurses, midwives and allied health professionals pursuing a clinical academic career. BMJ Open, 2021, 11, e043270.	0.8	22

#	ARTICLE	IF	CITATIONS
19	FC 074 POOLED EFFICACY AND CARDIOVASCULAR SAFETY RESULTS OF 3 PLACEBO-CONTROLLED AND 1 DARBEPOETIN ALFA-CONTROLLED STUDIES OF ROXADUSTAT FOR TREATMENT OF ANAEMIA IN PATIENTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
20	MO256 THE TREATMENT EFFECT OF RAS BLOCKADE ON PROTEINURIA IN IGA NEPHROPATHY PATIENTS AS A SURROGATE FOR RENAL EVENTS AND DECLINE IN EGFR: AN ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
21	The Non-Coding RNA Landscape in IgA Nephropathy—Where Are We in 2021?. <i>Journal of Clinical Medicine</i> , 2021, 10, 2369.	1.0	1
22	FC 040 INTERIM RESULTS OF PHASE 1 AND 2 TRIALS TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND CLINICAL ACTIVITY OF BION-1301 IN PATIENTS WITH IGA NEPHROPATHY. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	8
23	MO326 CORTICOSTEROIDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF REPORTED ADVERSE EVENTS IN RANDOMISED CONTROLLED TRIALS. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
24	FC 030 CONTACTIN-1 IS A NOVEL ANTIGEN IN IDIOPATHIC MEMBRANOUS GLOMERULONEPHRITIS AND IN CIDP-ASSOCIATED GLOMERULONEPHRITIS. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
25	FC 073 REGIONAL EFFICACY AND SAFETY RESULTS OF ROXADUSTAT COMPARED WITH PLACEBO OR DARBEPOETIN ALFA IN NON-DIALYSIS-DEPENDENT (NDD) CHRONIC KIDNEY DISEASE (CKD) PATIENTS WITH ANAEMIA. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
26	MO283 IMPACT OF VIS649, AN APRIL-NEUTRALIZING IGG2 MONOCLONAL ANTIBODY, ON TETANUS- AND DIPHTHERIA-TOXOID VACCINATION-ELICITED IMMUNE RESPONSES IN HEALTHY VOLUNTEERS: PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
27	MO230A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF ATRASENTAN IN PATIENTS WITH IGA NEPHROPATHY (THE ALIGN STUDY). <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
28	Differential expression of microRNA miR-150-5p in IgA nephropathy as a potential mediator and marker of disease progression. <i>Kidney International</i> , 2021, 99, 1127-1139.	2.6	35
29	Identifying Information Needs of Patients With IgA Nephropathy Using an Innovative Social Media—stepped Analytical Approach. <i>Kidney International Reports</i> , 2021, 6, 1317-1325.	0.4	10
30	MO258 SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF VIS649, AN APRIL-NEUTRALIZING IGG2 MONOCLONAL ANTIBODY, IN HEALTHY VOLUNTEERS: PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE STUDY. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	5
31	MO246 ESTIMATING DELAY IN TIME TO ESKD FOR TREATMENT EFFECTS ON PROTEINURIA IN IGA NEPHROPATHY AND FSGS*. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	2
32	MO286 DESIGN OF A PH1, MULTICENTER TRIAL TO INVESTIGATE THE SAFETY, TOLERABILITY, PK/PD OF BION-1301 IN HEALTHY VOLUNTEERS AND ADULTS WITH IGAN AND A MULTICENTER, OPEN-LABEL EXTENSION STUDY FOR IGAN PATIENTS WHO PARTICIPATED IN A PRIOR TRIAL OF BION-1301. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
33	MO540 CARDIOVASCULAR OUTCOMES ASSOCIATED WITH ACHIEVED HAEMOGLOBIN LEVEL IN POOLED PHASE 3 STUDIES OF ROXADUSTAT IN NON-DIALYSIS-DEPENDENT PATIENTS WITH ANAEMIA. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
34	MO148A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LNP023 IN PRIMARY IGA NEPHROPATHY PATIENTS. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	3
35	An Update on the Current State of Management and Clinical Trials for IgA Nephropathy. <i>Journal of Clinical Medicine</i> , 2021, 10, 2493.	1.0	31
36	A genome-wide association study suggests correlations of common genetic variants with peritoneal solute transfer rates in patients with kidney failure receiving peritoneal dialysis. <i>Kidney International</i> , 2021, 100, 1101-1111.	2.6	13

#	ARTICLE	IF	CITATIONS
37	Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES). <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1616-1628.	0.4	76
38	SGLT-2 inhibition in IgA nephropathy: the new standard of care?. <i>Kidney International</i> , 2021, 100, 24-26.	2.6	33
39	Anticipating, experiencing and overcoming challenges in clinical academic training. <i>British Journal of Health Care Management</i> , 2021, 27, 1-8.	0.1	2
40	A Pilot Study to Predict Risk of IgA Nephropathy Progression Based on miR-204 Expression. <i>Kidney International Reports</i> , 2021, 6, 2179-2188.	0.4	12
41	Is IgA nephropathy the same disease in different parts of the world?. <i>Seminars in Immunopathology</i> , 2021, 43, 707-715.	2.8	27
42	Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES). <i>Advances in Therapy</i> , 2021, 38, 5361-5380.	1.3	48
43	MicroRNA-23b-3p Deletion Induces an IgA Nephropathy-like Disease Associated with Dysregulated Mucosal IgA Synthesis. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2561-2578.	3.0	12
44	Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies. <i>Advances in Therapy</i> , 2021, 38, 5345-5360.	1.3	39
45	KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. <i>Kidney International</i> , 2021, 100, S1-S276.	2.6	782
46	Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. <i>Kidney International</i> , 2021, 100, 753-779.	2.6	325
47	Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular disease. <i>Kidney International</i> , 2021, 100, 881-893.	2.6	7
48	A focus group study of self-management in patients with glomerular disease.. <i>Kidney International Reports</i> , 2021, 7, 56-67.	0.4	2
49	IgA nephropathy: a perspective for 2021. <i>Seminars in Immunopathology</i> , 2021, 43, 625-626.	2.8	5
50	Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1002-1009.	0.4	66
51	Should we STOP immunosuppression for IgA nephropathy? Long-term outcomes from the STOP-IgAN trial. <i>Kidney International</i> , 2020, 98, 836-838.	2.6	6
52	IgA Nephropathy Genetic Risk Score to Estimate the Prevalence of IgA Nephropathy in UK Biobank. <i>Kidney International Reports</i> , 2020, 5, 1643-1650.	0.4	15
53	International consensus definitions of clinical trial outcomes for kidney failure: 2020. <i>Kidney International</i> , 2020, 98, 849-859.	2.6	65
54	The association of muscle size, strength and exercise capacity with all-cause mortality in non-dialysis-dependent CKD patients. <i>Clinical Physiology and Functional Imaging</i> , 2020, 40, 399-406.	0.5	6

#	ARTICLE	IF	CITATIONS
55	Inhibition of the Lectin Pathway of the Complement System as a Novel Approach in the Management of IgA Vasculitis-Associated Nephritis. <i>Nephron</i> , 2020, 144, 453-458.	0.9	17
56	Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy. <i>Kidney International Reports</i> , 2020, 5, 2032-2041.	0.4	84
57	Monitoring Immune Responses in IgA Nephropathy: Biomarkers to Guide Management. <i>Frontiers in Immunology</i> , 2020, 11, 572754.	2.2	24
58	Macrophage interactions with collecting duct epithelial cells are capable of driving tubulointerstitial inflammation and fibrosis in immunoglobulin A nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1865-1877.	0.4	5
59	The Metalloproteinase ADAMTS5 Is Expressed by Interstitial Inflammatory Cells in IgA Nephropathy and Is Proteolytically Active on the Kidney Matrix. <i>Journal of Immunology</i> , 2020, 205, 2243-2254.	0.4	6
60	Why Target the Gut to Treat IgA Nephropathy?. <i>Kidney International Reports</i> , 2020, 5, 1620-1624.	0.4	37
61	P0500RESULTS OF A PHASE 1 TRIAL TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF BION-1301 IN HEALTHY VOLUNTEERS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0
62	Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 673-684.	2.2	66
63	Whole-genome sequencing of a sporadic primary immunodeficiency cohort. <i>Nature</i> , 2020, 583, 90-95.	13.7	148
64	P0344NEFECONÂ® (BUDESONIDE) SELECTIVELY REDUCES CIRCULATING LEVELS OF BAFF (BLYS) AND SOLUBLE BCMA AND TACI IN IGA NEPHROPATHY. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	5
65	M0001ROXADUSTAT FOR THE TREATMENT OF ANAEMIA IN CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS: A PHASE 3, RANDOMISED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	2
66	M0039THE 24-WEEK INTERIM ANALYSIS RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY OF ATACICEPT IN PATIENTS WITH IGA NEPHROPATHY AND PERSISTENT PROTEINURIA. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	11
67	P0228THE NEFIGARD TRIAL: THE EFFECT OF NEFECONÂ® (BUDESONIDE) IN PATIENTS WITH PRIMARY IGA NEPHROPATHY AT RISK OF DEVELOPING END-STAGE RENAL DISEASE. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0
68	Biological variation of cardiac troponins in chronic kidney disease. <i>Annals of Clinical Biochemistry</i> , 2020, 57, 162-169.	0.8	4
69	The authors reply. <i>Kidney International</i> , 2020, 97, 214-215.	2.6	0
70	Randomized, Controlled Trial of Tacrolimus and Prednisolone Monotherapy for Adults with De Novo Minimal Change Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 209-218.	2.2	38
71	Artificial intelligence and machine learning in nephropathology. <i>Kidney International</i> , 2020, 98, 65-75.	2.6	57
72	Improving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction Tool. <i>Kidney International</i> , 2020, 98, 1009-1019.	2.6	35

#	ARTICLE	IF	CITATIONS
73	Immunoglobulin A nephropathy and IgA vasculitis (HSP). , 2020, , C21.8.1-C21.8.1.P61.		1
74	Phosphatidylethanolamine binding protein-4 (PEBP4) is increased in IgA nephropathy and is associated with IgA-positive B-cells in affected kidneys. Journal of Autoimmunity, 2019, 105, 102309.	3.0	14
75	Association between native T1 mapping of the kidney and renal fibrosis in patients with IgA nephropathy. BMC Nephrology, 2019, 20, 256.	0.8	23
76	Peritoneal Ultrafiltration for Heart Failure: Lessons from a Randomized Controlled Trial. Peritoneal Dialysis International, 2019, 39, 486-489.	1.1	12
77	FP201 INTERIM RESULTS FROM AN ONGOING PHASE 2 STUDY EVALUATING THE USE OF A MASP-2 INHIBITOR FOR THE TREATMENT OF IGA NEPHROPATHY (IGAN). Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
78	Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. Nature Communications, 2019, 10, 5120.	5.8	160
79	From expression footprints to causal pathways: contextualizing large signaling networks with CARNIVAL. Npj Systems Biology and Applications, 2019, 5, 40.	1.4	96
80	Implementing the Kidney Health Initiative Surrogate Efficacy Endpoint in Patients With IgA Nephropathy (the PROTECT Trial). Kidney International Reports, 2019, 4, 1633-1637.	0.4	26
81	Galactose-deficient IgA1 in skin and serum from patients with skin-limited and systemic IgA vasculitis. Journal of the American Academy of Dermatology, 2019, 81, 1078-1085.	0.6	15
82	208.â€f GALACTOSE DEFICIENT IGA1 (GD-IGA1) IN SKIN AND SERUM FROM PATIENTS WITH SKIN-LIMITED AND SYSTEMIC IGA VASCULITIS. Rheumatology, 2019, 58, .	0.9	2
83	The Iron Biology Status of Peritoneal Dialysis Patients May be a Risk Factor for Development of Infectious Peritonitis. Peritoneal Dialysis International, 2019, 39, 362-374.	1.1	5
84	Standardized Outcomes in Nephrologyâ€”Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease. Kidney International, 2019, 95, 1280-1283.	2.6	20
85	IgA nephropathy: â€œState of the artâ€: a report from the 15th International Symposium on IgA Nephropathy celebrating the 50th anniversary of its first description. Kidney International, 2019, 95, 750-756.	2.6	17
86	Pregnancy in IgA Nephropathy: An Effect on Renal Outcome?. American Journal of Nephrology, 2019, 49, 212-213.	1.4	1
87	Biological variation of measured and estimated glomerular filtration rate in patients with chronic kidney disease. Kidney International, 2019, 96, 429-435.	2.6	63
88	Is immunoglobulin A nephropathy different in different ethnic populations?. Nephrology, 2019, 24, 885-895.	0.7	55
89	New strategies and perspectives on managing IgA nephropathy. Clinical and Experimental Nephrology, 2019, 23, 577-588.	0.7	55
90	Biomarkers to Predict Progression in IgA Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1421-1423.	2.2	6

#	ARTICLE	IF	CITATIONS
91	Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 268-280.	2.6	198
92	Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 281-295.	2.6	135
93	Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 469-481.	2.2	128
94	Reduced proximal tubular expression of protein endocytic receptors in proteinuria is associated with urinary receptor shedding. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 934-943.	0.4	12
95	New insights into the pathogenesis of IgA nephropathy. <i>Pediatric Nephrology</i> , 2018, 33, 763-777.	0.9	97
96	MicroRNAs: a new avenue to understand, investigate and treat immunoglobulin A nephropathy?. <i>CKJ: Clinical Kidney Journal</i> , 2018, 11, 29-37.	1.4	20
97	Treatment of IgA Nephropathy: Evolution Over Half a Century. <i>Seminars in Nephrology</i> , 2018, 38, 531-540.	0.6	17
98	Aberrant Glycosylation of the IgA1 Molecule in IgA Nephropathy. <i>Seminars in Nephrology</i> , 2018, 38, 461-476.	0.6	61
99	A qualitative study of the perspectives of key stakeholders on the delivery of clinical academic training in the East Midlands. <i>JRSM Open</i> , 2018, 9, 205427041774184.	0.2	3
100	Study protocol: responding to the needs of patients with IgA nephropathy, a social media approach. <i>CKJ: Clinical Kidney Journal</i> , 2018, 11, 474-478.	1.4	1
101	Protocol and rationale for the first South Asian 5-year prospective longitudinal observational cohort study and biomarker evaluation investigating the clinical course and risk profile of IgA nephropathy: GRACE IgANI cohort. <i>Wellcome Open Research</i> , 2018, 3, 91.	0.9	6
102	Galactosylation of IgA1 Is Associated with Common Variation in C1GALT1. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2158-2166.	3.0	93
103	Evidence from the Oxford Classification cohort supports the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy. <i>Kidney International</i> , 2017, 91, 235-243.	2.6	62
104	Assessing the stability and suitability of haematology parameters for diagnosing and monitoring iron deficiency. <i>International Journal of Laboratory Hematology</i> , 2017, 39, e132-e134.	0.7	2
105	Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. <i>Lancet, The</i> , 2017, 389, 2117-2127.	6.3	278
106	Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. <i>Kidney International</i> , 2017, 91, 1014-1021.	2.6	748
107	β1,4-galactosyltransferase 1 is a novel receptor for IgA in human mesangial cells. <i>Kidney International</i> , 2017, 92, 1458-1468.	2.6	49
108	TO013 PROTEINURIA REDUCTION IN IGA NEPHROPATHY BY NEFECON, A TARGETED‑RELEASE FORMULATION OF BUDESONIDE - RESULTS FROM THE NEFIGAN TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, iii82-iii83.	0.4	2

#	ARTICLE	IF	CITATIONS
109	Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort. <i>Pediatric Nephrology</i> , 2017, 32, 139-150.	0.9	71
110	A Multicenter Study of the Predictive Value of Crescents in IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 691-701.	3.0	228
111	Targeted-release budesonide therapy for IgA nephropathy – Authors' reply. <i>Lancet, The</i> , 2017, 390, 2625-2626.	6.3	2
112	IgA nephropathy: driving innovation with a rare renal disease registry. <i>Journal of Kidney Care</i> , 2017, 2, 205-211.	0.1	3
113	The Effect of Resistance Exercise on Inflammatory and Myogenic Markers in Patients with Chronic Kidney Disease. <i>Frontiers in Physiology</i> , 2017, 8, 541.	1.3	32
114	MP401DIFFERENTIAL MICRORNA EXPRESSION IN SKELETAL MUSCLE OF HUMAN CKD PATIENTS AND HEALTHY CONTROLS. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i473-i474.	0.4	3
115	Should Immunosuppressive Therapy Be Used in Slowly Progressive IgA Nephropathy?. <i>American Journal of Kidney Diseases</i> , 2016, 68, 184-186.	2.1	2
116	Low α -defensin gene copy number increases the risk for IgA nephropathy and renal dysfunction. <i>Science Translational Medicine</i> , 2016, 8, 345ra88.	5.8	35
117	The MEST score provides earlier risk prediction in IgA nephropathy. <i>Kidney International</i> , 2016, 89, 167-175.	2.6	190
118	Is IgA Nephropathy a Single Disease?. , 2016, , 3-17.		3
119	Effect of Immunosuppressive Drugs on the Changes of Serum Galactose-Deficient IgA1 in Patients with IgA Nephropathy. <i>PLoS ONE</i> , 2016, 11, e0166830.	1.1	23
120	Intervention Associated Acute Kidney Injury and Long-Term Cardiovascular Outcomes. <i>American Journal of Nephrology</i> , 2015, 42, 285-294.	1.4	33
121	The solution structures of native and patient monomeric human IgA1 reveal asymmetric extended structures: implications for function and IgAN disease. <i>Biochemical Journal</i> , 2015, 471, 167-185.	1.7	22
122	Long-Term Therapeutic Plasma Exchange to Prevent End-Stage Kidney Disease in Adult Severe Resistant Henoch-Schonlein Purpura Nephritis. <i>Case Reports in Nephrology</i> , 2015, 2015, 1-5.	0.2	3
123	SP011SERUM IGA1 HINGE REGION O-GLYCOSYLATION IS A HERITABLE TRAIT IN CAUCASIANS. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii384-iii384.	0.4	0
124	SP083TGF- β 1 RELEASE FROM PTEC IS STIMULATED BY GALACTOSE-DEFICIENT POLYMERIC IGA1. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii406-iii406.	0.4	0
125	Emerging therapies in immunoglobulin A nephropathy. <i>Nephrology</i> , 2015, 20, 788-800.	0.7	19
126	Vascular Endothelial Growth Factor-A165b Is Protective and Restores Endothelial Glycocalyx in Diabetic Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1889-1904.	3.0	112

#	ARTICLE	IF	CITATIONS
127	The Genetics of IgA Nephropathy: An Overview from Western Countries. <i>Kidney Diseases (Basel)</i> , 2014, 1, 1-14.	0.7843	1
128	Gluten and IgA nephropathy: you are what you eat?. <i>Kidney International</i> , 2015, 88, 215-218.	2.6	11
129	Progressive Resistance Exercise Training in CKD: A Feasibility Study. <i>American Journal of Kidney Diseases</i> , 2015, 66, 249-257.	2.1	83
130	The role of IgA in proximal tubular cell activation and tubulointerstitial scarring in IgA nephropathy. <i>Lancet</i> , 2014, 383, S34.	6.3	0
131	Immunoglobulin A Nephropathy and Related Disorders. , 2014, , 185-192.		2
132	Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. <i>Kidney International</i> , 2014, 86, 828-836.	2.6	373
133	Evidence-based classification of glomerular pathology. <i>Kidney International</i> , 2014, 86, 1059.	2.6	3
134	Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. <i>Nature Genetics</i> , 2014, 46, 1187-1196.	9.4	505
135	IgA Nephropathy and Henoch-Schönlein Purpura. , 2014, , 203-213.		0
136	IgA Nephropathy. , 2014, , 467-475.		0
137	Spleen Tyrosine Kinase Is Important in the Production of Proinflammatory Cytokines and Cell Proliferation in Human Mesangial Cells following Stimulation with IgA1 Isolated from IgA Nephropathy Patients. <i>Journal of Immunology</i> , 2012, 189, 3751-3758.	0.4	65
138	An update on the pathogenesis and treatment of IgA nephropathy. <i>Kidney International</i> , 2012, 81, 833-843.	2.6	136
139	Primary IgA Nephropathy: New Insights Into Pathogenesis. <i>Seminars in Nephrology</i> , 2011, 31, 349-360.	0.6	44
140	Interpretation and management of abnormal dipstick urinalysis. <i>Medicine</i> , 2011, 39, 312-316.	0.2	4
141	Inherited IgA glycosylation pattern in IgA nephropathy and HSP nephritis: where do we go next?. <i>Kidney International</i> , 2011, 80, 8-10.	2.6	16
142	The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. <i>Kidney International</i> , 2010, 77, 921-927.	2.6	181
143	Immune complex formation in IgA nephropathy: CD89 a "saint" or a "sinner"? <i>Kidney International</i> , 2010, 78, 1211-1213.	2.6	25
144	Immunoglobulin A nephropathy and Henoch-Schönlein purpura. , 2010, , 3971-3977.		0

#	ARTICLE	IF	CITATIONS
145	Immunoglobulin A nephropathy and Henoch-Schönlein purpura. , 2010, , 3971-3977.		0
146	The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. <i>Kidney International</i> , 2009, 76, 546-556.	2.6	892
147	Sugars and immune complex formation in IgA nephropathy. <i>Nature Reviews Nephrology</i> , 2009, 5, 612-614.	4.1	8
148	Immune complex formation in IgA nephropathy: a case of the 'right' antibodies in the 'wrong' place at the 'wrong' time?. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 3620-3623.	0.4	47
149	Abnormal IgD and IgA1 O-glycosylation in hyperimmunoglobulinaemia D and periodic fever syndrome. <i>Clinical and Experimental Medicine</i> , 2009, 9, 291-296.	1.9	7
150	The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. <i>Kidney International</i> , 2009, 76, 534-545.	2.6	1,028
151	Other Non-Immunomodulatory Agents. , 2009, , 349-367.		1
152	Secondary IgA Nephropathy. <i>Seminars in Nephrology</i> , 2008, 28, 27-37.	0.6	99
153	IgA Nephropathy: Introduction. <i>Seminars in Nephrology</i> , 2008, 28, 1-3.	0.6	1
154	Cystic renal disease presenting in pregnancy: a novel presentation of oral-facial-digital syndrome type 1. <i>CKJ: Clinical Kidney Journal</i> , 2008, 1, 23-25.	1.4	2
155	B-cell O-galactosyltransferase activity, and expression of O-glycosylation genes in bone marrow in IgA nephropathy. <i>Kidney International</i> , 2008, 73, 1128-1136.	2.6	41
156	Is sialylation of IgA the agent provocateur of IgA nephropathy?. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 2176-2178.	0.4	6
157	Chapter 18 Pharmacology and drug use in kidney disease. , 2008, , .		0
158	Chapter 2 Fluid and electrolyte disorders. , 2008, , .		0
159	Chapter 1 Assessment of renal disease. , 2008, , .		0
160	Chapter 17 Malignancy of the kidney and urinary tract. , 2008, , .		0
161	Chapter 13 Dialysis. , 2008, , .		0
162	Chapter 15 Inherited renal disease. , 2008, , .		0

#	ARTICLE	IF	CITATIONS
163	Chapter 4 The kidney in systemic disease. , 2008, , .		0
164	Chapter 3 Glomerular disease. , 2008, , .		0
165	Chapter 12 Special problems in chronic kidney disease. , 2008, , .		0
166	Chapter 9 Hypertension. , 2008, , .		0
167	Chapter 6 Chronic interstitial disease. , 2008, , .		0
168	Chapter 5 Tubular disease. , 2008, , .		0
169	Chapter 8 Renal stone disease. , 2008, , .		0
170	Chapter 11 Chronic kidney disease (CKD). , 2008, , .		0
171	Chapter 10 Acute kidney injury (AKI). , 2008, , .		0
172	Chapter 16 Structural and congenital abnormalities. , 2008, , .		0
173	Chapter 7 Urinary tract infection. , 2008, , .		0
174	Chapter 14 Renal transplantation. , 2008, , .		0
175	Mutant mice provide new insight into the role of (mis-)glycation in IgA nephropathy and other glomerular diseases. Nephrology Dialysis Transplantation, 2007, 22, 1518-1520.	0.4	3
176	T-cell homing receptor expression in IgA nephropathy. Nephrology Dialysis Transplantation, 2007, 22, 2540-2548.	0.4	42
177	A spoonful of sugar helps the proteinuria go down?. Nephrology Dialysis Transplantation, 2007, 23, 813-815.	0.4	3
178	Urine proteomics: the present and future of measuring urinary protein components in disease. Cmaj, 2007, 177, 361-368.	0.9	183
179	International IgA Nephropathy Network Clinico-Pathological Classification of IgA Nephropathy. , 2007, 157, 13-18.		12
180	The pathogenic role of IgA1 O-linked glycosylation in the pathogenesis of IgA nephropathy (Review) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.7	56

#	ARTICLE	IF	CITATIONS
181	What to do with patients with abnormal dipstick urinalysis. <i>Medicine</i> , 2007, 35, 365-367.	0.2	13
182	Immunopathogenesis of IgAN. <i>Seminars in Immunopathology</i> , 2007, 29, 427-443.	2.8	64
183	Treatment of IgA nephropathy. <i>Kidney International</i> , 2006, 69, 1934-1938.	2.6	133
184	O-Glycosylation of Serum IgD in IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 1192-1199.	3.0	77
185	O-Glycosylation of Serum IgA1 Antibodies against Mucosal and Systemic Antigens in IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 3520-3528.	3.0	104
186	IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 2088-2097.	3.0	401
187	Inhibitors Directed towards Caspase-1 and -3 Are Less Effective than Pan Caspase Inhibition in Preventing Renal Proximal Tubular Cell Apoptosis. <i>Nephron Experimental Nephrology</i> , 2004, 96, e39-e51.	2.4	27
188	Pathogenesis of IgA nephropathy. <i>Seminars in Nephrology</i> , 2004, 24, 197-217.	0.6	110
189	Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: Observations in three patients. <i>Kidney International</i> , 2001, 60, 969-973.	2.6	269
190	Identification of a novel Fc γ receptor expressed by human mesangial cells. <i>Kidney International</i> , 2000, 57, 1936-1948.	2.6	50
191	Outcome of Acute Renal Failure Following Surgical Repair of Ruptured Abdominal Aortic Aneurysms. <i>European Journal of Vascular and Endovascular Surgery</i> , 2000, 20, 163-168.	0.8	48
192	Exaggerated systemic antibody response to mucosal <i>Helicobacter pylori</i> infection in IgA nephropathy. <i>American Journal of Kidney Diseases</i> , 1999, 33, 1049-1057.	2.1	69
193	Analysis of IgA1 O-Glycans in IgA Nephropathy by Fluorophore-Assisted Carbohydrate Electrophoresis. <i>Journal of the American Society of Nephrology: JASN</i> , 1999, 10, 1763-1771.	3.0	117
194	Contactin-1 Antibodies Link Autoimmune Neuropathies to Nephrotic Syndrome. <i>SSRN Electronic Journal</i> , 0, , .	0.4	8
195	IgA Nephropathy in Adults and Children. , 0, , 170-182.		0